 Tiziana Life Sciences PLC NASDAQ:TLSA LON:TILS said it is confident that it is well positioned to advance its drug development programs to their next respective value inflection points. Final results on Tuesday showed cash of 48.2mln in the bank at the end of December, after a year when the company made a loss before tax of 21.8mln as RD and operating costs increased as it continued to progress a pipeline of drugs to treat rare cancers and autoimmune and inflammatory diseases. 